Search results
Showing 1126 to 1140 of 1336 results for primary care
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
America showed an aromatase inhibitor (exemestane) to be effective for the primary prevention of breast cancer. However, there has been...
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
Evidence summaries: process guide
CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)
NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .
NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .
compared by accessing medical records and through qualitative interviews. Primary outcomes are long‑term physical morbidity, pain after...
scanning equipment. Currently, there are no definitive studies in primary or secondary care evaluating whether the addition...
NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued [GID-HST10038]
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.